CSIMarket
 
Orphazyme A  (ORPH)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) 36
 Net Income (TTM) (Millions $) -627
 Cash Flow (TTM) (Millions $) 124
 Capital Exp. (TTM) (Millions $) 2

Orphazyme A
A biopharmaceutical company that is dedicated to discovering novel therapies for a range of rare neurodegenerative diseases, including lysosomal storage disorders, protein aggregation, and mitochondrial dysfunction.

Orphazyme A is a Danish company that was founded in 2009, and it is headquartered in Copenhagen. The company has a strong focus on developing treatments for rare diseases, which are often overlooked by larger pharmaceutical companies. Its mission is to improve the quality of life for patients suffering from these conditions by providing effective and innovative therapies.

The company's main focus is on the development of arimoclomol, a candidate drug that has shown promising results in the treatment of several rare neurological disorders. Arimoclomol is a small molecule that acts by increasing the production of heat shock proteins, which are responsible for helping the body repair damaged proteins and prevent protein misfolding, a process that is implicated in many neurodegenerative diseases.

Orphazyme A has conducted several clinical trials to test the safety and efficacy of arimoclomol in patients with different rare diseases. One of the most promising trials was conducted in patients with Niemann-Pick disease type C (NPC), a rare genetic disorder characterized by a deficiency in the NPC protein, which leads to the accumulation of cholesterol in the brain and other tissues.

In this trial, arimoclomol demonstrated significant improvements in several important disease parameters, including motor function, speech, and swallowing ability. The drug was also found to be safe and well-tolerated in these patients.

Orphazyme A has several ongoing clinical trials exploring the use of arimoclomol in other rare diseases, including amyotrophic lateral sclerosis (ALS) and sporadic inclusion body myositis (sIBM). The company is also exploring other small molecules that target different aspects of protein aggregation and misfolding.

In addition to its focus on drug development, Orphazyme A is also committed to patient advocacy and awareness-raising. The company works closely with patient organizations and advocates to ensure that the needs of rare disease patients are addressed and that their voices are heard.

Orphazyme A is a leading player in the field of rare diseases and has made significant progress in developing innovative therapies for these conditions. Its dedication to patient advocacy and awareness-raising is an important part of its mission to improve the lives of those suffering from rare diseases.


   Company Address: Ole Maal?¸es Vej 3 Copenhagen N 0
   Company Phone Number: 28 98 90 55   Stock Exchange / Ticker: ORPH
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Orphazyme A's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com